Arkuda Therapeutics (Series A)
Funding Details
- Awarder
- Inbox
- Date Award
- November 08, 2019
- Vertical
- Biotechnology
- Funding URL
- View Funding Page
- Funding Amount:
- $44,000,000
Company Info
- Founding Year
- 2019
- Organizations Involved
- Atlas Venture, Pfizer Ventures, Tekla Capital Management LLC, BioInnovation Capital
- Founders
- Gerhard Koenig
- Company Description
- Arkuda Therapeutics is a biotechnology company leveraging new insights into progranulin and lysosomal biology to develop medicines to change the trajectory of neurodegenerative disease. Arkuda's lead compounds aim to correct progranulin deficiency and lysosomal dysfunction in GRN-related frontotemporal dementia (FTD-GRN), a genetically-defined subtype of frontotemporal dementia caused by an autosomal dominant mutation in the GRN gene.
- Market
- Neurodegenerative diseases
- Location
- Cambridge, MA, USA
- Coinvestors
- Atlas Venture, Pfizer Ventures, funds managed by Tekla Capital Management LLC, BioInnovation Capital